We investigated the mutational landscape of mTOR signaling cascade in hepatocellular carcinomas (HCCs) with chronic hepatitis B (HBV) background, aiming to evaluate and delineate mutation-dependent mechanism of mTOR hyper-activation in hepatocarcinogenesis. We performed next-generation sequencing on human HCC samples and cell line panel. Systematic mutational screening of mTOR pathway-related genes was undertaken and mutant genes were evaluated based on their recurrence. Protein expressions of TSC1, TSC2 and pRPS6 were assessed by immunohistochemistry in human HCC samples. Rapamycin sensitivity was estimated by colony formation assay in HCC cell lines and the treatment was further tested using our patient derived tumor xenograft (PDTX) models. Results: We identified and confirmed multiple mTOR components as recurrently mutated in HBV-associated HCCs. Of significance, we detected frequent (16.2%, n = 18/111) mutations of TSC1 and TSC2 genes in the HCC samples. The spectrum of TSC1/2 mutations likely disrupts the endogenous gene functions in suppressing the downstream mTOR activity through different mechanisms and leading to more aggressive tumor behavior. Mutational disruption of TSC1 and TSC2 was also observed in HCC cell lines and our PDTX models. TSC-mutant cells exhibited reduced colony forming ability upon Rapamycin treatment. With the use of the biologically relevant TSC2-mutant PDTXs, we demonstrated the therapeutic benefits of the hyper-sensitivity towards Rapamycin treatment. Taken together, our findings suggest the significance of previously undocumented mutation-dependent mTOR hyper-activation and frequent TSC1/2 mutations in HBV-associated HCCs. They define a molecular subset of HCC having genetic aberrations in mTOR signaling, with potential significance of effective specific drug therapy. Citation Format: Daniel Wai Ho, Lo Kong Chan, Yung Tuen Chiu, Iris Ming Xu, Ronnie Poon, Tan To Cheung, Chung Ngai Tang, Victor Tang, Irene Lo, Polly Lam, Derek Yau, Miao Xin Li, Chun Ming Wong, Irene O. L. Ng. TSC1/2 mutations define a molecular subset of HCC with aggressive behavior and treatment implication [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4389. doi:10.1158/1538-7445.AM2017-4389
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. It ranks third amongst cancer-related deaths worldwide owing to its late symptom presentation and lack of effective treatment regimens. Compared to normal cells, cancer cells experience distinctly higher amount of oxidative stress from increased reactive oxygen species (ROS) generation contributed by metabolic alterations, or its hypoxic microenvironment. Cancer cells also have a greater capacity of antioxidant production to maintain redox homeostasis. Immense generation of NADPH, a major metabolite and antioxidant is found in cancer cells to combat ROS as confirmed in our previous studies as we identified the folate cycle and pentose phosphate pathway (PPP) as major metabolic pathways responsible for NADPH production in human HCC. NADPH is an electron donor which can reduce and activate different antioxidant systems. The thioredoxin system is a ubiquitously-expressed mammalian antioxidant system activated by NADPH. The transmission of an electron from NADPH to TXN, the ROS-scavenging member of the thioredoxin system, is modulated by thioredoxin reductase 1 (TXNRD1). TXRND1 is the sole activating-enzyme of the thioredoxin system, playing a vital role in maintaining intracellular redox homeostasis. Furthermore, TXNRD1 was found to be significantly over-expressed in human HCC correlated with poor clinical prognosis and patient survival. Genetic inhibition of TXNRD1 via shRNA-knockdown significantly induced oxidative stress which suppressed HCC cell proliferation in vitro and liver tumor formation orthotopically implanted in vivo. Interestingly, TXNRD1-inhibition-induced oxidative stress rendered HCC cells more sensitive towards Sorafenib, its conventional therapeutic agent. This was highlighted by a dramatic induction of ROS-induced apoptosis in vitro and suppression tumor growth in vivo. NRF2, a transcription factor and master regulator against oxidative stress, was confirmed to bind with TXNRD1 using ChIP assay. Both genetic inhibition and pharmacological activation of NRF2 in HCC cells confirmed the dependent relationship between NRF2 and TXNRD1. Therapeutically, pharmacological inhibition of the thioredoxin system using the TXNRD1 inhibitor auranofin greatly sensitized HCC cells towards sorafenib. The synergism was observed through significant induction of ROS resulting in significant cell death in vitro and suppression of tumor formation in vivo. Our investigation demonstrated the induction of oxidative stress, as a result of thioredoxin system inhibition, rendered HCC cells more sensitive towards therapeutic treatment. Contrasting the widely-known, tumorigenic role of ROS, we now shed light on a paradigm-shifting strategy which ROS may be used as a therapeutic adjuvant to combat cancer. Citation Format: Derek Lee, Iris Ming Jing Xu, David Kung Chun Chiu, Robin Kit Ho Lai, Chun Ming Wong, Irene Oi Lin Ng, Carmen Chak Lui Wong. Oxidative stress induction through TXNRD1 inhibition as a therapeutic strategy in hepatocellular carcinoma treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2445.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.